Pharma BD Deal Intelligence
Roche Holding AG / Seragon Pharmaceuticals, Inc.
2014 · Acquisition/Merger · $1.7B · Complete
Announcement Sentiment
63
Positive
Roche/Genentech acquired private San Diego biotech Seragon Pharmaceuticals (spun out of Aragon/J&J) for $725M cash plus up to $1B in milestones, gaining a portfolio of oral SERDs led by ARN-810 for ER+ breast cancer. The deal seeded what later became Roche's giredestrant program.
Did it work? Outcome assessment Strategic verdict
Failed to Achieve
Pipeline outcome
Assets Terminated
Assessment window: 5yr post-close.
Key facts
Announced Jul 02, 2014 Closed Aug 04, 2014 Deal value $1.7B Deal type Acquisition/Merger Therapeutic area ER-positive breast cancer Indications ER-positive breast cancer Key assets ARN-810 (giredestrant predecessor) selective estrogen receptor degraders Mechanism Oral selective estrogen receptor degrader (SERD)
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals
The Pharma Closeout — Deal Intelligence Database.
Announcement Sentiment and Outcome Score from sourced facts.Home ·
Deals ·
Methodology ·
About